Random non-fasting C-peptide testing can identify patients with insulin-treated type 2 diabetes at high risk of hypoglycaemia
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
AIMS/HYPOTHESIS: The aim of this study was to determine whether random non-fasting C-peptide (rCP) measurement can be used to assess hypoglycaemia risk in insulin-treated type 2 diabetes. METHODS: We compared continuous glucose monitoring-assessed SD of blood glucose and hypoglycaemia duration in 17 patients with insulin-treated type 2 diabetes and severe insulin deficiency (rCP < 200 pmol/l) and 17 matched insulin-treated control patients with type 2 diabetes but who had preserved endogenous insulin (rCP > 600 pmol/l). We then assessed the relationship between rCP and questionnaire-based measures of hypoglycaemia in 256 patients with insulin-treated type 2 diabetes and a comparison group of 209 individuals with type 1 diabetes. RESULTS: Continuous glucose monitoring (CGM)-assessed glucose variability and hypoglycaemia was greater in individuals with rCP < 200 pmol/l despite similar mean glucose. In those with low vs high C-peptide, SD of glucose was 4.2 (95% CI 3.7, 4.6) vs 3.0 (2.6, 3.4) mmol/l (p < 0.001). In the low-C-peptide vs high-C-peptide group, the proportion of individuals experiencing sustained hypoglycaemia ≤ 4 mmol/l was 94% vs 41% (p < 0.001), the mean rate of hypoglycaemia was 5.5 (4.4, 6.7) vs 2.1 (1.4, 2.9) episodes per person per week (p = 0.004) and the mean duration was 630 (619, 643) vs 223 (216, 230) min per person per week (p = 0.01). Hypoglycaemia ≤ 3 mmol/l was infrequent in individuals with preserved C-peptide (1.8 [1.2, 2.6] episodes per person per week vs 0.4 [0.1, 0.8] episodes per person per week for low vs high C-peptide, p = 0.04) and only occurred at night. In a population-based cohort with insulin-treated type 2 diabetes, self-reported hypoglycaemia was twice as frequent in those with rCP < 200 pmol/l (OR 2.0, p < 0.001) and the rate of episodes resulting in loss of consciousness or seizure was five times higher (OR 5.0, p = 0.001). The relationship between self-reported hypoglycaemia and C-peptide was similar in individuals with type 1 and type 2 diabetes. CONCLUSIONS/INTERPRETATION: Low rCP is associated with increased glucose variability and hypoglycaemia in patients with insulin-treated type 2 diabetes and represents a practical, stable and inexpensive biomarker for assessment of hypoglycaemia risk.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Epidemiology of severe hypoglycemia in the diabetes control and complications trial
(1991) · The American Journal of Medicine · doi:10.1016/0002-9343(91)80085-z · Cited by 807
Epidemiology of severe hypoglycemia in the Diabetes Control and Complications Trial
(1991) · The American Journal of Medicine · doi:10.1016/0002-9343(91)90605-w · Cited by 807
Hypoglycemia in the Diabetes Control and Complications Trial
The Diabetes Control and Complications Trial Research Group (1997) · Diabetes · doi:10.2337/diab.46.2.271 · Cited by 746
Steffes, M. W., Sibley, S., Jackson, M., & Thomas, W. (2003) · Diabetes Care · doi:10.2337/diacare.26.3.832 · Cited by 695
Three-year efficacy of complex insulin regimens in type 2 diabetes
Holman, R. R., Farmer, A. J., Davies, M. J., Levy, J. C., Darbyshire, J. L., Keenan, J. F., & Paul, S. K. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905479 · Cited by 667 · cited 3×
“To assess whether differences between groups were due to confounding by differences in clinical features associated with hypoglycaemia and insulin type [21], we assessed the OR (proportions, logistic regression) and rate ratio (questions 5 Diabetologia”
BackgroundMethodClarke, W. L., Cox, D. J., Gonder-Frederick, L. A., Julian, D., Schlundt, D., & Polonsky, W. (1995) · Diabetes Care · doi:10.2337/diacare.18.4.517 · Cited by 651
Hypoglycaemia in insulin‐treated Type 2 diabetes: frequency, symptoms and impaired awareness
Henderson, J. N., Allen, K. V., Deary, I. J., & Frier, B. M. (2003) · Diabetic Medicine · doi:10.1046/j.1464-5491.2003.01072.x · Cited by 287
Lachin, J. M., McGee, P., Palmer, J. P., & for the DCCT/EDIC Research Group (2014) · Diabetes · doi:10.2337/db13-0881 · Cited by 283 · cited 2×
“This threshold of 200 pmol/l is commonly described as identifying absolute insulin deficiency, although modern assays can measure below this range [7, 8] and a relationship between hypoglycaemia and lower levels of C-peptide has been described [9, 10].”
BackgroundResultOram, R. A., McDonald, T. J., Shields, B. M., Hudson, M. M., Shepherd, M. H., Hammersley, S., Pearson, E. R., Hattersley, A. T., & on behalf of the UNITED Team (2015) · Diabetes Care · doi:10.2337/dc14-0871 · Cited by 133 · cited 1×
“This threshold of 200 pmol/l is commonly described as identifying absolute insulin deficiency, although modern assays can measure below this range [7, 8] and a relationship between hypoglycaemia and lower levels of C-peptide has been described [9, 10].”
BackgroundSelf-citationLow levels of C‐peptide have clinical significance for established Type 1 diabetes
Kuhtreiber, W. M., Washer, S. L. L., Hsu, E., Zhao, M., Reinhold, P., Burger, D., Zheng, H., & Faustman, D. L. (2015) · Diabetic Medicine · doi:10.1111/dme.12850 · Cited by 131
Hope, S. V., Wienand-Barnett, S., Shepherd, M., King, S. M., Fox, C., Khunti, K., Oram, R. A., Knight, B. A., Hattersley, A. T., Jones, A. G., et al. (2016) · British Journal of General Practice · doi:10.3399/bjgp16x684961 · Cited by 87
Self-citationJin, S.-M., Kim, T.-H., Bae, J. C., Hur, K. Y., Lee, M.-S., Lee, M.-K., & Kim, J. H. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2014.02.003 · Cited by 74
Hope, S. V., Knight, B. A., Shields, B. M., Hattersley, A. T., McDonald, T. J., & Jones, A. G. (2016) · Diabetic Medicine · doi:10.1111/dme.13142 · Cited by 68
Self-citation
Cited by
Thomas, N. J., Lynam, A. L., Hill, A. V., Weedon, M. N., Shields, B. M., Oram, R. A., McDonald, T. J., Hattersley, A. T., & Jones, A. G. (2019) · Diabetologia · doi:10.1007/s00125-019-4863-8 · Cited by 183
Approach to the patient with mody-monogenic diabetes
Broome, D. T., Pantalone, K. M., Kashyap, S. R., & Philipson, L. H. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa710 · Cited by 159
Maddaloni, E., Bolli, G. B., Frier, B. M., Little, R. R., Leslie, R. D., Pozzilli, P., & Buzzetti, R. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14785 · Cited by 135
Lynam, A., McDonald, T., Hill, A., Dennis, J., Oram, R., Pearson, E., Weedon, M., Hattersley, A., Owen, K., Shields, B., et al. (2019) · BMJ Open · doi:10.1136/bmjopen-2019-031586 · Cited by 72
Foteinopoulou, E., Clarke, C. A. L., Pattenden, R. J., Ritchie, S. A., McMurray, E. M., Reynolds, R. M., Arunagirinathan, G., Gibb, F. W., McKnight, J. A., & Strachan, M. W. J. (2021) · Diabetic Medicine · doi:10.1111/dme.14449 · Cited by 61
Metadata
- Authors
- Hope, S. V., Knight, B. A., Shields, B. M., Hill, A. V., Choudhary, P., Strain, W. D., McDonald, T. J., & Jones, A. G.
- Venue
- Diabetologia
- Published
- 2017-10-05
- Volume
- 61
- Issue
- 1
- Pages
- 66-74
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- OpenAlex
- W2760883322
- Cited by
- 41
- References
- 13
- FWCI
- 3.71
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.